Prevail Therapeutics (NASDAQ:PRVL) Stock Rating Lowered by BidaskClub

BidaskClub cut shares of Prevail Therapeutics (NASDAQ:PRVL) from a buy rating to a hold rating in a research note released on Saturday, BidAskClub reports.

Other equities analysts have also recently issued reports about the company. Citigroup started coverage on Prevail Therapeutics in a research report on Thursday, March 5th. They set a buy rating and a $24.00 target price for the company. ValuEngine upgraded Prevail Therapeutics from a hold rating to a buy rating in a research report on Thursday, April 2nd. Piper Sandler started coverage on Prevail Therapeutics in a research report on Thursday, April 9th. They set an overweight rating and a $20.00 target price for the company. Wedbush boosted their target price on Prevail Therapeutics from $19.00 to $22.00 and gave the stock an outperform rating in a research report on Tuesday, May 26th. Finally, Zacks Investment Research cut Prevail Therapeutics from a strong-buy rating to a hold rating in a research report on Thursday, May 28th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $20.00.

Shares of NASDAQ PRVL opened at $14.90 on Friday. The stock has a market cap of $501.40 million and a PE ratio of -6.51. Prevail Therapeutics has a fifty-two week low of $7.41 and a fifty-two week high of $19.96. The company has a debt-to-equity ratio of 0.06, a quick ratio of 14.32 and a current ratio of 14.32. The stock has a fifty day moving average of $16.36 and a 200-day moving average of $15.76.

Prevail Therapeutics (NASDAQ:PRVL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.06). On average, sell-side analysts predict that Prevail Therapeutics will post -2.33 EPS for the current year.

A number of large investors have recently made changes to their positions in PRVL. BlackRock Inc. grew its holdings in shares of Prevail Therapeutics by 59.3% during the 1st quarter. BlackRock Inc. now owns 1,133,979 shares of the company’s stock worth $13,823,000 after acquiring an additional 422,205 shares during the period. State Street Corp lifted its position in Prevail Therapeutics by 68.8% in the 4th quarter. State Street Corp now owns 104,886 shares of the company’s stock valued at $1,660,000 after acquiring an additional 42,767 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Prevail Therapeutics by 5.5% during the 1st quarter. Bank of New York Mellon Corp now owns 225,154 shares of the company’s stock valued at $2,745,000 after buying an additional 11,664 shares during the period. Citigroup Inc. lifted its holdings in shares of Prevail Therapeutics by 61.8% during the 1st quarter. Citigroup Inc. now owns 6,669 shares of the company’s stock valued at $81,000 after buying an additional 2,546 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Prevail Therapeutics during the 1st quarter valued at $159,000. Institutional investors own 80.50% of the company’s stock.

Prevail Therapeutics Company Profile

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Featured Story: How does a security become overbought?

Analyst Recommendations for Prevail Therapeutics (NASDAQ:PRVL)

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.